Long-Term Performance of Point-of-Care Hemoglobin A1c Assays

Sujaytha Paknikar, Rohan Sarmah, Losika Sivaganeshan, Adam Welke, Al Rizzo, Kirk Larson, Marc Rendell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Point-of-care (POC) testing of HbA1c is used as a time-efficient tool to improve treatment and management planning for diabetes in the clinic setting. HbA1c values are the basis for monitoring ongoing response to treatment and to make adjustments to diabetes therapy. Yet, there is ongoing controversy as to the accuracy of POC assays. Diabetes is a lifelong disease, so comparability of results over a long period of time is needed to follow the response to treatment. Methods: We compared the Afinion™ automated boronate affinity assay and the DCA Vantage immunoassay-based POC techniques to the Tosoh G8 and Bio-Rad Variant II ion-exchange high-performance liquid chromatography (HPLC) central laboratory methods in a study lasting 3 years. College of American Pathology Survey results and American Proficiency testing were utilized to assess the external validity of the POC techniques. Results: Despite high correlations among the 4 techniques, there were significant and variable differences obtained over time. The Biorad values varied from 0.1 to 0.4% higher than the Afinion values. The DCA results were usually higher than the Afinion values, but fell below the Afinion results in the last 6 months of our study. Both POC techniques gave systematically lower values than the Tosoh measurements, and both the POC and the central laboratory measurements showed variable differences from the National Glycohemoglobin Standardization Program values over the duration of this study. Conclusions: All who rely on POC methods as well as on central laboratory measurement of HbA1c must understand the potential limitations of these assays. The assessment of diabetes blood sugar control should proceed from the evaluation of HbA1c combined with review of plasma glucose and of self-monitored blood glucose values.

Original languageEnglish (US)
Pages (from-to)1308-1315
Number of pages8
JournalJournal of diabetes science and technology
Volume10
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Point-of-Care Systems
Hemoglobin
Medical problems
Assays
Hemoglobins
Glucose
Blood Glucose
Blood
High performance liquid chromatography
Testing
Pathology
Sugars
Standardization
Ion exchange
Ion Exchange
Plasmas
Immunoassay
Planning
Monitoring
High Pressure Liquid Chromatography

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Bioengineering
  • Medicine(all)
  • Biomedical Engineering

Cite this

Paknikar, S., Sarmah, R., Sivaganeshan, L., Welke, A., Rizzo, A., Larson, K., & Rendell, M. (2016). Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. Journal of diabetes science and technology, 10(6), 1308-1315. https://doi.org/10.1177/1932296816645362

Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. / Paknikar, Sujaytha; Sarmah, Rohan; Sivaganeshan, Losika; Welke, Adam; Rizzo, Al; Larson, Kirk; Rendell, Marc.

In: Journal of diabetes science and technology, Vol. 10, No. 6, 01.11.2016, p. 1308-1315.

Research output: Contribution to journalArticle

Paknikar, S, Sarmah, R, Sivaganeshan, L, Welke, A, Rizzo, A, Larson, K & Rendell, M 2016, 'Long-Term Performance of Point-of-Care Hemoglobin A1c Assays', Journal of diabetes science and technology, vol. 10, no. 6, pp. 1308-1315. https://doi.org/10.1177/1932296816645362
Paknikar S, Sarmah R, Sivaganeshan L, Welke A, Rizzo A, Larson K et al. Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. Journal of diabetes science and technology. 2016 Nov 1;10(6):1308-1315. https://doi.org/10.1177/1932296816645362
Paknikar, Sujaytha ; Sarmah, Rohan ; Sivaganeshan, Losika ; Welke, Adam ; Rizzo, Al ; Larson, Kirk ; Rendell, Marc. / Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. In: Journal of diabetes science and technology. 2016 ; Vol. 10, No. 6. pp. 1308-1315.
@article{e43f0caca56c491dae55a5dd4b265c86,
title = "Long-Term Performance of Point-of-Care Hemoglobin A1c Assays",
abstract = "Background: Point-of-care (POC) testing of HbA1c is used as a time-efficient tool to improve treatment and management planning for diabetes in the clinic setting. HbA1c values are the basis for monitoring ongoing response to treatment and to make adjustments to diabetes therapy. Yet, there is ongoing controversy as to the accuracy of POC assays. Diabetes is a lifelong disease, so comparability of results over a long period of time is needed to follow the response to treatment. Methods: We compared the Afinion™ automated boronate affinity assay and the DCA Vantage immunoassay-based POC techniques to the Tosoh G8 and Bio-Rad Variant II ion-exchange high-performance liquid chromatography (HPLC) central laboratory methods in a study lasting 3 years. College of American Pathology Survey results and American Proficiency testing were utilized to assess the external validity of the POC techniques. Results: Despite high correlations among the 4 techniques, there were significant and variable differences obtained over time. The Biorad values varied from 0.1 to 0.4{\%} higher than the Afinion values. The DCA results were usually higher than the Afinion values, but fell below the Afinion results in the last 6 months of our study. Both POC techniques gave systematically lower values than the Tosoh measurements, and both the POC and the central laboratory measurements showed variable differences from the National Glycohemoglobin Standardization Program values over the duration of this study. Conclusions: All who rely on POC methods as well as on central laboratory measurement of HbA1c must understand the potential limitations of these assays. The assessment of diabetes blood sugar control should proceed from the evaluation of HbA1c combined with review of plasma glucose and of self-monitored blood glucose values.",
author = "Sujaytha Paknikar and Rohan Sarmah and Losika Sivaganeshan and Adam Welke and Al Rizzo and Kirk Larson and Marc Rendell",
year = "2016",
month = "11",
day = "1",
doi = "10.1177/1932296816645362",
language = "English (US)",
volume = "10",
pages = "1308--1315",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "6",

}

TY - JOUR

T1 - Long-Term Performance of Point-of-Care Hemoglobin A1c Assays

AU - Paknikar, Sujaytha

AU - Sarmah, Rohan

AU - Sivaganeshan, Losika

AU - Welke, Adam

AU - Rizzo, Al

AU - Larson, Kirk

AU - Rendell, Marc

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Point-of-care (POC) testing of HbA1c is used as a time-efficient tool to improve treatment and management planning for diabetes in the clinic setting. HbA1c values are the basis for monitoring ongoing response to treatment and to make adjustments to diabetes therapy. Yet, there is ongoing controversy as to the accuracy of POC assays. Diabetes is a lifelong disease, so comparability of results over a long period of time is needed to follow the response to treatment. Methods: We compared the Afinion™ automated boronate affinity assay and the DCA Vantage immunoassay-based POC techniques to the Tosoh G8 and Bio-Rad Variant II ion-exchange high-performance liquid chromatography (HPLC) central laboratory methods in a study lasting 3 years. College of American Pathology Survey results and American Proficiency testing were utilized to assess the external validity of the POC techniques. Results: Despite high correlations among the 4 techniques, there were significant and variable differences obtained over time. The Biorad values varied from 0.1 to 0.4% higher than the Afinion values. The DCA results were usually higher than the Afinion values, but fell below the Afinion results in the last 6 months of our study. Both POC techniques gave systematically lower values than the Tosoh measurements, and both the POC and the central laboratory measurements showed variable differences from the National Glycohemoglobin Standardization Program values over the duration of this study. Conclusions: All who rely on POC methods as well as on central laboratory measurement of HbA1c must understand the potential limitations of these assays. The assessment of diabetes blood sugar control should proceed from the evaluation of HbA1c combined with review of plasma glucose and of self-monitored blood glucose values.

AB - Background: Point-of-care (POC) testing of HbA1c is used as a time-efficient tool to improve treatment and management planning for diabetes in the clinic setting. HbA1c values are the basis for monitoring ongoing response to treatment and to make adjustments to diabetes therapy. Yet, there is ongoing controversy as to the accuracy of POC assays. Diabetes is a lifelong disease, so comparability of results over a long period of time is needed to follow the response to treatment. Methods: We compared the Afinion™ automated boronate affinity assay and the DCA Vantage immunoassay-based POC techniques to the Tosoh G8 and Bio-Rad Variant II ion-exchange high-performance liquid chromatography (HPLC) central laboratory methods in a study lasting 3 years. College of American Pathology Survey results and American Proficiency testing were utilized to assess the external validity of the POC techniques. Results: Despite high correlations among the 4 techniques, there were significant and variable differences obtained over time. The Biorad values varied from 0.1 to 0.4% higher than the Afinion values. The DCA results were usually higher than the Afinion values, but fell below the Afinion results in the last 6 months of our study. Both POC techniques gave systematically lower values than the Tosoh measurements, and both the POC and the central laboratory measurements showed variable differences from the National Glycohemoglobin Standardization Program values over the duration of this study. Conclusions: All who rely on POC methods as well as on central laboratory measurement of HbA1c must understand the potential limitations of these assays. The assessment of diabetes blood sugar control should proceed from the evaluation of HbA1c combined with review of plasma glucose and of self-monitored blood glucose values.

UR - http://www.scopus.com/inward/record.url?scp=85009517865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009517865&partnerID=8YFLogxK

U2 - 10.1177/1932296816645362

DO - 10.1177/1932296816645362

M3 - Article

VL - 10

SP - 1308

EP - 1315

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 6

ER -